Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
[90] RCT	413 people In review [88]	Drowsiness 43% with trifluoperazine 25% with placebo Absolute numbers not reported	Significance not assessed
[90] RCT	413 people In review [88] 11 RCTs in this analysis	Extrapyramidal reactions and movement disorders 17% with trifluoperazine 8% with placebo Absolute numbers not reported	Significance not assessed
[89] Systematic review	450 people Data from 1 RCT	Proportion of people with at least 1 adverse effect 145/223 (65%) with quetiapine 114/227 (50%) with placebo	OR 1.84 95% CI 1.26 to 2.69 P <0.002	Small effect size	placebo
[89] Systematic review	2262 people 4 RCTs in this analysis	Proportion of people with extrapyramidal adverse effects 63/1369 (5%) with quetiapine 25/893 (3%) with placebo	OR 1.80 95% CI 1.12 to 2.90 P <0.016	Small effect size	placebo
[89] Systematic review	2201 people 4 RCTs in this analysis	Mean change in weight (kg) with quetiapine with placebo Absolute numbers not reported	Mean difference 0.63 kg 95% CI 0.40 kg to 0.86 kg P <0.00001	Effect size not calculated	placebo
[89] Systematic review	437 people Data from 1 RCT	Increase in prolactin (ng/mL) with quetiapine with placebo Absolute numbers not reported	Mean difference +0.70 ng/mL 95% CI –1.09 ng/mL to +2.49 ng/mL P = 0.44		Not significant